Advanced genetic testing opens new treatment options for nearly one in three cancer patients, study finds
A new study from London Health Sciences Centre Research Institute (LHSCRI) shows that expanded genetic testing can help match cancer patients with more personalized treatment options, with nearly one in three found eligible for therapies not typically used for their specific type of cancer based on the unique DNA of their tumor.
A study from London Health Sciences Centre Research Institute (LHSCRI) reveals that expanded genetic testing can significantly improve cancer treatment options for nearly one in three patients. Standard testing typically examines a limited number of genes specific to a patient's cancer type, but advanced next-generation sequencing tests thousands of cancer-related genes simultaneously.
This broader approach uncovered genetic changes in 79% of the 554 patients studied, many of which were not detected through standard testing. These findings identified alternative therapies, clinical trials, off-label treatments, and compassionate access programs that were previously unavailable, offering new hope to patients with limited treatment choices.
The study, published in The Journal of Molecular Diagnostics, emphasizes the potential of this evidence to guide physicians in connecting patients to the most effective treatments based on their unique tumor DNA.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
